Results 81 to 90 of about 455,173 (344)

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

The structure and function of vertebrate fibroblast growth factor receptor 1 [PDF]

, 2002
The vertebrate fibroblast growth factor receptor 1 (FGFR1) is alternatively spliced generating multiple splice variants that are differentially expressed during embryo development and in the adult body.
Groth, C., Lardelli, M.
core  

Seprase: An overview of an important matrix serine protease [PDF]

, 2008
Seprase or Fibroblast Activation Protein (FAP) is an integral membrane serine peptidase, which has been shown to have gelatinase activity. Seprase has a dual function in tumour progression.
Abbott, Abbott, Abbott, Acharya, Adams, Adams, Aertgeerts, Aimes, Alcolado, Aoyama, Ariga, Artym, Bangert, Barrett, Bauvois, Bermpohl, Birney, Bissell, Brendan F. O'Connor, Brown, Busek, Chen, Chen, Chen, Chen, Cheng, Cheng, Christiansen, Collins, Corpet, De Wever, Del Rosso, Dolznig, Dvorak, Edosada, Edosada, Fassnacht, Fidler, Fink, Flentke, Fulop, Garcia-Horsman, Garin-Chesa, Gerner, Ghersi, Ghersi, Ghersi, Gilmore, Goldstein, Goldstein, Goodman, Gorrell, Guex, Hofheinz, Huang, Huber, Huber, Ibrahim, Iwasa, Jin, Kelly, Kelly, Kelly, Kelly, Kloft, Koyama, Lee, Lee, Lee, Lee, Lee, Levy, Levy, Levy, Loeffler, Mathew, Mersmann, Milner, Monsky, Mori, Mueller, Nicholas, Niedermeyer, Niedermeyer, Niedermeyer, Oertel, Okada, Okada, Ollis, Pamela O'Brien, Park, Pineiro-Sanchez, Ramirez-Montagut, Rennex, Rettig, Rettig, Rettig, Rettig, Rosenblum, Samel, Scanlan, Schechter, Scott, Scott, Sieweke, Skubitz, Stremenova, Sun, Tahtis, Tran, Wang, Wang, Welt, Welt, Wesley, Zhang   +115 more
core   +1 more source

Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment

Molecular Oncology, EarlyView.
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho, Yubin Hah, Eunsik Yun, Hye In Ka, Aram Lee, Sora Han, Dawn Lee, Sung Wook Kim, Jong Hoon Park, Byung Su Kwon, Young Yang, Jongmin Kim   +11 more
wiley   +1 more source

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. [PDF]

, 2015
Fibroblast growth factors (FGFs) and their receptors (FGFRs) are transmembrane growth factor receptors with wide tissue distribution. FGF/FGFR signaling is involved in neoplastic behavior and also development, differentiation, growth, and survival.
Helsten, Teresa, Kurzrock, Razelle, Schwaederle, Maria   +2 more
core   +2 more sources

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Biological implications of a discrete mathematical model for collagen deposition and alignment in dermal wound repair [PDF]

, 2000
We deveiop a novel mathematical model for collagen deposition and alignment during dermal wound healing. We focus on the interactions between fibroblasts, modelled as discrete entities, and a continuous extracellular matrix composed of collagen and a ...
Dallon, J. C., Ferguson, M., Maini, P. K., Sherratt, J. A.   +3 more
core   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. [PDF]

, 2010
The most severe clinical and pathologic manifestations of systemic sclerosis (SSc) are the result of a fibrotic process characterized by the excessive and often progressive deposition of collagen and other connective tissue macromolecules in skin and ...
Castro, Susan V., Jimenez, Sergio A., Piera-Velazquez, Sonsoles   +2 more
core   +2 more sources

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source